Yale Startup IsoPlexis Raises $1.25M to Advance their Cell
Decoding Micro-device  YaleUniversity's picture Printer-friendly
versionPrinter-friendly versionPDF versionPDF version  Yale
bioscience tools company IsoPlexis recently closed on a $1.25
million Series A round with investments from Spring Mountain
Capital, Connecticut Innovations and others. The startup is
developing a single cell immunoassay device and software that
provides in-depth understanding of immune and cancer cell
activity. It was formed through the Technology Commercialization
Program (TCP) which connects professional and graduate school
students at Yale with patented faculty inventions at the cutting
edge of science and technology. The TCP is jointly run by the
Yale Office of Cooperative Research and the Yale Entrepreneurial
Institute. IsoPlexis also participated in the 2013 YEI
Fellowship and received a $100,000 investment from the YEI
Innovation Fund.  “We’re very excited by our progress and have
hired a team of talented bioscience, prog